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IMPORTANCE Animal studies have shown that the adolescent brain is sensitive to disruptions
in endocannabinoid signaling, resulting in altered neurodevelopment and lasting behavioral
effects. However, few studies have investigated ties between cannabis use and adolescent
brain development in humans.
OBJECTIVE To examine the degree to which magnetic resonance (MR) imaging–assessed
cerebral cortical thickness development is associated with cannabis use in a longitudinal
sample of adolescents.
DESIGN, SETTING, AND PARTICIPANTS Data were obtained from the community-based
IMAGEN cohort study, conducted across 8 European sites. Baseline data used in the present
study were acquired from March 1, 2008, to December 31, 2011, and follow-up data were
acquired from January 1, 2013, to December 31, 2016. A total of 799 IMAGEN participants
were identified who reported being cannabis naive at study baseline and had behavioral
and neuroimaging data available at baseline and 5-year follow-up. Statistical analysis was
performed from October 1, 2019, to August 31, 2020.
MAIN OUTCOMES AND MEASURES Cannabis use was assessed at baseline and 5-year follow-up
with the European School Survey Project on Alcohol and Other Drugs. Anatomical MR images
were acquired with a 3-dimensional T1-weighted magnetization prepared gradient echo
sequence. Quality-controlled native MR images were processed through the CIVET pipeline,
version 2.1.0.
RESULTS The study evaluated 1598 MR images from 799 participants (450 female
participants [56.3%]; mean [SD] age, 14.4 [0.4] years at baseline and 19.0 [0.7] years at
follow-up). At 5-year follow-up, cannabis use (from 0 to >40 uses) was negatively associated
with thickness in left prefrontal (peak: t785 = –4.87, cluster size = 1558 vertices;
P = 1.10 × 10−6, random field theory cluster corrected) and right prefrontal (peak: t785 = –4.27,
cluster size = 1551 vertices; P = 2.81 × 10−5, random field theory cluster corrected) cortices.
There were no significant associations between lifetime cannabis use at 5-year follow-up and
baseline cortical thickness, suggesting that the observed neuroanatomical differences did not
precede initiation of cannabis use. Longitudinal analysis revealed that age-related cortical
thinning was qualified by cannabis use in a dose-dependent fashion such that greater use,
from baseline to follow-up, was associated with increased thinning in left prefrontal (peak:
t815.27 = –4.24, cluster size = 3643 vertices; P = 2.28 × 10
−8, random field theory cluster
corrected) and right prefrontal (peak: t813.30 = –4.71, cluster size = 2675 vertices;
P = 3.72 × 10−8, random field theory cluster corrected) cortices. The spatial pattern of
cannabis-related thinning was associated with age-related thinning in this sample (r = 0.540;
P < .001), and a positron emission tomography–assessed cannabinoid 1 receptor–binding map
derived from a separate sample of participants (r = −0.189; P < .001). Analysis revealed that
thinning in right prefrontal cortices, from baseline to follow-up, was associated with
attentional impulsiveness at follow-up.
CONCLUSIONS AND RELEVANCE Results suggest that cannabis use during adolescence is
associated with altered neurodevelopment, particularly in cortices rich in cannabinoid 1 receptors
and undergoing the greatest age-related thickness change in middle to late adolescence.
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C annabis is a commonly used psychoactive drug, par-ticularly among adolescents and young adults. Rela-tive to the general population, past-year prevalence
rates of cannabis use are greatest among teenagers, and more
than one-third of 12th graders in the United States report using
cannabis in the past year.1,2 Seventy-eight percent of first-
time cannabis users are between the ages of 12 and 20 years.3
These prevalence rates raise concern as cannabis use during
adolescence has been linked to enduring impairments of
executive functioning and impulse control.4 Such longitudi-
nal associations appear specific to cannabis use and indepen-
dent of concomitant alcohol use; however, the neurobiologi-
cal mechanisms that might mediate a long-term behavioral
association with cannabis use remain unclear.4 The potential
association of cannabis use with adolescent development rep-
resents an increasingly relevant public health issue, particu-
larly given evidence of increased problematic cannabis use
among adolescents in areas where recreational cannabis use
has been legalized.5
The transition from late adolescence to early adulthood is
characterized by significant structural change in the brain, most
notably in areas of the cerebral cortex that are known to ex-
hibit protracted developmental trajectories and undergo rela-
tively late myelination.6-9 Extant research studies suggest that
changes in endocannabinoid signaling can have a significant
association with aspects of mammalian brain development.10,11
Evidence further indicates that the adolescent brain may be
particularly sensitive to disruptions in normative fluctua-
tions in endocannabinoid signaling, associated with altered
neurodevelopment and behavior.12-15 Despite such findings in
the animal literature, few longitudinal neuroimaging studies
have examined putative ties between cannabis use and ado-
lescent brain development, to our knowledge.
Here, we examined the association between cannabis
use and cerebral cortical development in a longitudinal,
community-based sample of adolescents. From the larger
IMAGEN sample, we identified participants who reported being
cannabis naive at study baseline and had neuroimaging data
available at study baseline and 5-year follow-up. First, in a se-
ries of cross-sectional analyses, we examined the extent to
which lifetime cannabis use was associated with cortical thick-
ness at 5-year follow-up (approximately 19 years of age). To test
the temporality of this association, we then examined the ex-
tent to which cortical thickness at age 14 years was associated
with lifetime cannabis use at 5-year follow-up. In our primary
longitudinal analysis, a linear mixed-effects model (LMM) was
implemented to test the degree to which initiation of canna-
bis use was associated with age-related cortical thickness
change (from ages 14 to 19 years). Follow-up analyses were
conducted to test the extent to which cannabis-related corti-
cal thinning was associated with aspects of impulsive behav-
ior. We also tested the association between the longitudinally
derived map of cannabis-related cortical thinning and posi-
tron emission tomography (PET)–derived cannabinoid 1
(CB1) receptor availability (collected from an independent
sample of young adults) with the hypothesis that areas dem-
onstrating cannabis-related thinning would exhibit, on aver-
age, relatively greater CB1 receptor availability. We further
hypothesized that cannabis-related thinning would be most
evident in cortical regions undergoing the greatest structural
change during the developmental window studied.
Methods
Sample
Neuroimaging and behavioral data were obtained from the
IMAGEN study,16 conducted across 8 European sites, which
includes 2223 adolescents recruited from schools at approxi-
mately 14 years of age (range, 12.9-15.7 years). Baseline data
used in the present cohort study were acquired from March
1, 2008, to December 31, 2011, and follow-up data were
acquired from January 1, 2013, to December 31, 2016. Local
ethics research committees approved the study at each site
(London, England: Psychiatry, Nursing and Midwifery
Research Ethics Subcommittee, Waterloo Campus, King’s
College London; Nottingham, England: University of Not-
tingham Medical School Ethics Committee; Mannheim, Ger-
many: Medizinische Fakultaet Mannheim, Ruprecht Karl
Universitaet Heidelberg and Ethik-Kommission II an der
Fakultaet fuer Kliniksche Medizin Mannheim; Dresden, Ger-
many: Ethikkommission der Medizinischen Fakultaet Carl
Gustav Carus, TU Dresden Medizinische Fakultaet; Ham-
burg, Germany: Ethics Board, Hamburg Chamber of Physi-
cians; Paris, France: CPP IDF VII (Comité de protection des
personnes Ile de France), ID RCB: 2007-A00778-45 Septem-
ber 24, 2007; Dublin, Ireland: TCD School of Psychology
REC; and Berlin, Germany: Ethics Committee of the Faculty
of Psychology). Written consent was obtained from the
adolescent’s parent or guardian, and verbal assent was
obtained from the adolescent. We identified 799 participants
who reported being cannabis naive on the European School
Survey Project on Alcohol and Other Drugs (ESPAD)17 at
study baseline and had behavioral and quality-controlled
neuroimaging data available at study baseline and 5-year
follow-up.
Key Points
Question To what extent is cannabis use associated with
magnetic resonance imaging–measured cerebral cortical thickness
development during adolescence?
Findings In this cohort study, linear mixed-effects model analysis
using 1598 magnetic resonance images from 799 participants
revealed that cannabis use was associated with accelerated
age-related cortical thinning from 14 to 19 years of age in
predominantly prefrontal regions. The spatial pattern of
cannabis-related cortical thinning was significantly associated
with a positron emission tomography–assessed map of
cannabinoid 1 receptor availability.
Meaning Results suggest that cannabis use during middle
to late adolescence may be associated with altered cerebral
cortical development, particularly in regions rich in cannabinoid 1
receptors.
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Substance Use Measures
Substance use was assessed at baseline and 5-year follow-up
with ESPAD,17 a self-report questionnaire that measures use
of alcohol, nicotine, and cannabis as well as other sub-
stances. Participants indicated how frequently they had used
each of the substances in their lifetime, in the past 12 months,
in the past 30 days, and in the past 7 days using a 7-point scale
(where 0 indicates never; 1, 1-2 times; 2, 3-5 times; 3, 6-9 times;
4, 10-19 times; 5, 20-39 times; and 6, ≥40 times).
The Alcohol Use Disorders Identification Test (AUDIT) is
a 10-item screening tool created by the World Health Organi-
zation that assesses alcohol consumption, drinking behav-
iors, and alcohol-associated problems.18 AUDIT was adminis-
tered to youths at baseline and follow-up. The AUDIT Alcohol
Consumption scale (AUDIT-C) was used in the present study
and is composed of items on AUDIT that explicitly assess
the amount and frequency of alcohol consumption.19,20
Impulsivity Measures
Given prior research suggesting that cannabis use has asso-
ciations with impulse control, we chose to examine associa-
tions between cannabis-related thinning and 3 domains of
impulsiveness (attentional, nonplanning, and motor)
assessed on the Barratt Impulsiveness Scale,21,22 a 30-item
self-report questionnaire that was administered at 5-year
follow-up in IMAGEN.
Cortical Thickness
Anatomical magnetic resonance (MR) images were acquired
with a 3-dimensional T1-weighted magnetization prepared
gradient echo sequence based on the Alzheimer’s Disease
Neuroimaging Initiative protocol.23 Quality-controlled na-
tive MR images were processed through the CIVET pipeline,
version 2.1.0 (Montreal Neurological Institute) using the
CBRAIN platform (Montreal Neurological Institute)24 and Com-
pute Canada25 (eAppendix 1 in the Supplement).
CB1 Receptor Availability
To test for possible associations between the spatial distribu-
tion of cannabis-related cortical thinning and a receptor for
the endocannabinoid system, we used a map of CB1 receptor
availability generated from healthy control participants in a
previously published study.26 Maps of CB1 receptor avail-
ability were generated using PET and the reversible ligand
[11C]OMAR in 21 men aged 18 to 35 years. The 21 individual
participant maps were averaged to provide an estimate of
CB1 receptor availability at each voxel. This mean PET vol-
ume was subsequently projected to a cortical surface model
in the Montreal Neurological Institute International Consor-
tium for Brain Mapping space.
Statistical Analysis
Statistical analysis was performed from October 1, 2019, to
August 31, 2020. Cortical thickness analysis was imple-
mented using SurfStat, a toolbox created for MATLAB (The
MathWorks Inc).27 In cross-sectional analyses, local cortical
thickness was regressed on lifetime cannabis use. Longi-
tudinal cortical thickness analysis was conducted using
LMMs.8,28-33 In LMMs, participant ID was entered as a random
effect to account for within-individual dependence. Change
in lifetime cannabis use (from baseline to 5-year follow-up) was
included as a time-invariant covariate. Age, total brain vol-
ume, sex, handedness, site, and consumption score on AUDIT
were controlled for in all analyses. To account for multiple
comparisons, random field theory correction was applied to
the cortical surface (eAppendix 2 in the Supplement).34 A ran-
dom field theory cluster–corrected significance threshold of
P < .05 was used for all cortical thickness analyses.
Results
Demographics and Cannabis Use
The study evaluated 1598 MR images from 799 participants
(450 female participants [56.3%]; mean [SD] age at baseline,
14.4 [0.4] years). Demographic information is summarized in
the Table and eTable 1 in the Supplement. Demographic in-
formation regarding excluded IMAGEN participants can be
found in eTable 2 in the Supplement. At follow-up, lifetime can-
nabis use ranged from 0 to more than 40 uses, with 208 par-
ticipants reporting 1 to 9 uses and 161 participants reporting
10 to more than 40 uses. Distribution of lifetime cannabis use
at 5-year follow-up is shown in eFigure 1 in the Supplement.
Descriptive statistics are provided for ESPAD substance use
items and AUDIT-C in eTables 3-6 in the Supplement. For fur-
ther details regarding demographic variables, see eAppendix
3 in the Supplement.
Cannabis Use and Cortical Thickness
Cross-Sectional
At 5-year follow-up, there was evidence of a dose-dependent
association between lifetime cannabis use and cortical thick-
ness (n = 799), with significant negative associations be-
tween lifetime cannabis use and thickness in left prefrontal
(peak: t785 = –4.87, cluster size = 1558 vertices; P = 1.10 × 10−6,
random field theory cluster corrected) and right prefrontal
(peak: t785 = –4.27, cluster size = 1551 vertices; P = 2.81 × 10−5,
random field theory cluster corrected) cortices (Figure 1). There
were no significant associations between baseline cortical
Table. Summary Statistics for Demographic Variables








Socioeconomic statusa 18.2 (3.7)
Verbal IQ 112.6 (13.0)
Performance IQ 109.6 (13.6)
a Details for the socioeconomic score can be found in eAppendix 1
of the Supplement.
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thickness and follow-up lifetime cannabis use, suggesting
that the neuroanatomical differences observed at 5-year
follow-up did not precede initiation of cannabis use. Even when
reducing the statistical threshold to P ≤ .005 uncorrected, only
several negative associations were revealed—and these areas
were well outside of those showing the 5-year follow-up as-
sociations (eFigure 2 in the Supplement).
Longitudinal
In line with the cross-sectional results, longitudinal LMM analy-
sis (799 participants and 1598 MR images) revealed a signifi-
cant time × cannabis interaction such that cannabis use was
associated with accelerated age-related cortical thinning in left
prefrontal (peak: t815.27 = –4.24, cluster size = 3643 vertices;
P = 2.28 × 10−8, random field theory cluster corrected) and right
prefrontal (peak: t813.30 = –4.71, cluster size = 2675 vertices;
P = 3.72 × 10−8, random field theory cluster corrected) corti-
ces (Figure 2 and Figure 3; eFigure 3 in the Supplement). Re-
sults were not meaningfully altered when controlling for base-
line age and length of time between study visits. Further, the
unthresholded t statistic map for the time × cannabis interac-
tion was significantly associated with a PET-derived map of
Figure 1. Cross-Sectional Results
P value cluster P value vertex
0.025.025 .050.05
P values
Brain areas where local cortical
thickness is negatively associated
with the dimensional measure of
lifetime cannabis use at 5-year
follow-up (N = 799). Random field
theory was used to correct for
multiple comparisons over the entire
cortical mantle. The figure is shown at
P  .05, random field theory
corrected. Blue areas are significant
at the cluster level, and red
corresponds to areas significant at
the vertex level. Measures were
controlled for age, total brain volume,
sex, handedness, Alcohol Use
Disorders Identification Test Alcohol
Consumption score, and site.
Figure 2. Longitudinal Linear Mixed-Effects Model Results




Brain areas where local cortical
thickness is associated with the
time × cannabis interaction in a linear
mixed-effects model analysis,
controlling for the main effects of
time point, lifetime cannabis use,
total brain volume, sex, handedness,
Alcohol Use Disorders Identification
Test Alcohol Consumption score,
and site (N = 799; 1598 magnetic
resonance imaging scans).
The figure is shown at P  .05 with a
whole-brain random field theory
correction. Blue shades correspond
to areas significant at the cluster level
and red shades to areas significant at
the vertex level.
Research Original Investigation Association of Cannabis Use During Adolescence With Neurodevelopment
E4 JAMA Psychiatry Published online June 16, 2021 (Reprinted) jamapsychiatry.com
Downloaded From: https://jamanetwork.com/ on 06/28/2021
CB1 receptor availability (collected on a separate sample of 21
healthy adults) (r = −0.189; P < .001), indicating that cortical
areas in which age-related thinning was qualified by canna-
bis partially overlapped with areas showing a higher density
of CB1 receptors as indexed by [11C]OMAR binding (Figure 4).
Given that PET data were collected on an all-male sample,
we reran our LMM using male participants only (n = 349 and
698 MR images). The t map for the time × cannabis interac-
tion in male participants was similar to results obtained when
male and female participants were analyzed together. Fur-
thermore, the unthresholded t statistic map for the time × can-
nabis interaction in male participants was significantly asso-
ciated with the PET-derived map of CB1 receptor availability
(r = −0.313; P < .001).
Age and Cortical Thickness
Next, longitudinal LMM analysis was implemented to charac-
terize the association between age and cortical thickness in the
sample of 799 participants who were cannabis naive at base-
line. Consistent with prior reports of cortical thickness devel-
opment, there was a significant main association of time point
with cortical thickness, with most areas of the cortex evidenc-
ing age-related thinning.7,8 The spatial pattern of cannabis-
related cortical thinning was correlated with the unthresh-
olded t statistic map for the association with time, indicating
that, on average, cannabis-related thinning was greater in
cortical regions evidencing the most significant age-related
thinning in this sample (r = 0.540; P < .001) (Figure 4).
Additional Covariates, Moderators,
and Cannabis Use Variables
Across all analyses, controlling for socioeconomic status, ver-
bal IQ, and performance IQ did not meaningfully alter re-
sults. In cross-sectional and longitudinal analyses, we exam-
ined sex as a potential moderator in the association between
cortical thickness and cannabis use. In cross-sectional analy-
ses, there was no significant sex × cannabis interaction on cor-
tical thickness. Similarly, in longitudinal analysis, a time × can-
nabis × sex interaction was not significantly associated with
cortical thickness, indicating that the association between



















Lifetime cannabis use (5-y follow-up), No. of uses
Right dorsomedial prefrontal clusterA



















Lifetime cannabis use (5-y follow-up), No. of uses
Left dorsomedial prefrontal clusterB
0 1-2 3-5 6-9 10-19 20-39 ≥40
A, Right dorsomedial prefrontal cluster from linear mixed-effects analysis. B, Left dorsomedial prefrontal cluster from linear mixed-effects analysis. The bar graphs
depict within-individual symmetrized percentage change (ie, change in cortical thickness, in millimeters per year, with respect to the mean cortical thickness across
both time points) for each cluster at varying levels of lifetime cannabis use (at 5-year follow-up). Error bars represent 95% confidence intervals. Brain figures shown
at P  .05 with a whole-brain random field theory correction. Blue shades correspond to areas significant at the cluster level, and orange shades to areas significant
at the vertex level.
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age-related thinning and cannabis use did not statistically dif-
fer between sexes. Nearly identical results were obtained when
all analyses were rerun using a binary cannabis use variable
(moderate and heavy users vs cannabis naive) with a between-
group design. See eAppendix 4, eFigure 4, and eFigure 5 in the
Supplement for details. Although alcohol consumption was
controlled for in the above analyses, co-occurring tobacco use
represents an additional potential confounder. At 5-year follow-
up, lifetime tobacco use was correlated with lifetime canna-
bis use on ESPAD (r = 0.573; P < .001). However, rerunning the
longitudinal analysis and including lifetime tobacco use as a
covariate resulted in largely consistent findings (eFigure 6 in
the Supplement).
Cannabis-Related Thinning and Impulsiveness
Cannabis-related cortical thinning in the right dorsomedial
prefrontal cortex accounted for unique variance in atten-
tional impulsiveness at 5-year follow-up while controlling for
sex, site, baseline age, baseline brain volume, baseline puber-
tal development, verbal IQ, and performance IQ (b = −0.119;
P = .003). Thus, accelerated thinning in the right dorsome-
dial prefrontal cortex was associated with the transition to can-
nabis use as well as greater attentional impulsiveness at 5-year
follow-up. This association held even when controlling for
baseline parent-reported and self-reported attention-deficit/
hyperactivity disorder symptoms (eAppendix 5 in the Supple-
ment). Exploratory follow-up analyses revealed no signifi-
cant associations between cannabis-associated thinning
and other psychopathologic and neurocognitive measures
(eAppendix 6 and eAppendix 7 in the Supplement).
Discussion
To our knowledge, the present investigation represents the larg-
est longitudinal neuroimaging study of cannabis use to date.
Results suggest that cannabis use during middle to late ado-
lescence may be associated with altered cortical develop-
ment, particularly in prefrontal regions rich in CB1 receptors
and exhibiting protracted maturational trajectories. Specifi-
cally, we found evidence of a dose-dependent association be-
tween cannabis use from baseline to 5-year follow-up and ac-
celerated cortical thinning during that same period, primarily
in prefrontal regions. Baseline cortical thickness was not as-
sociated with lifetime cannabis use at 5-year follow-up, sug-
gesting that the observed neuroanatomical associations with
lifetime cannabis use were not associated with preexisting dif-
ferences in brain structure. Results from longitudinal analy-
sis indicated that age-related cortical thinning was associ-
ated with cannabis use in a dose-dependent fashion such that
greater use from baseline to 5-year follow-up was associated
with increased rates of cortical thinning in predominantly pre-
frontal regions during that same period. Our results are cor-
roborated by convergence with PET mapping of CB1 receptor
availability; cortical areas in which the transition to cannabis
use was associated with accelerated age-related thinning were,
on average, cortical regions with increased CB1 receptor avail-
ability. Across analyses, we controlled for co-occurring alco-
hol consumption and confirmed that the associations with can-
nabis use persisted when covarying for nicotine use. Follow-up
analyses indicate a potential consequence of cannabis-
Figure 4. Topographical Overlap Between Age-Related Thinning, Cannabis Effect,










r = –0.19r = 0.54
Topographical overlap between
age-related cortical thinning in the
sample (n = 799), areas in which
age-related thinning was qualified by
cannabis use, and positron emission
tomography–assessed CB1 receptor
availability (collected from a separate
sample of 21 healthy adults).
The r values correspond to Pearson
correlation coefficients between
unthresholded vertex-level surface
maps. Please note that thresholds
have been lowered for visualization
purposes. Regional [11C]OMAR
volume distribution is shown at >1.4,
age-related thinning map is shown at
t < −15, and cannabis-related thinning
map is shown at t < −2.
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related cortical thinning, as cortical thinning in the right
dorsomedial prefrontal cortex from baseline to 5-year
follow-up was associated with attentional impulsiveness at
5-year follow-up.
Numerous cross-sectional studies have tested for brain
structural correlates of adolescent cannabis use, although find-
ings have been inconsistent.35-42 In general, when comparing
adolescent cannabis users with nonusers, cross-sectional stud-
ies have reported evidence of reduced volume and surface area
across frontal and parietal areas as well as reduced cortical
thickness in frontal regions.35,38,43 Other studies have found
evidence of increased volume and/or thickness in temporal
and cerebellar regions in adolescent cannabis users relative to
peers who did not use cannabis.37,41,42 However, some prior
studies have failed to reveal structural differences between
adolescent cannabis users and controls who did not use
cannabis.39,40 Few longitudinal neuroimaging studies have at-
tempted to test for associations between change in cannabis
use and change in brain structure. In a study of 30 adoles-
cents with heavy marijuana use and concomitant alcohol use,
Jacobus et al44 found evidence of attenuated age-related thin-
ning in comparison with controls, predominantly in frontal and
parietal regions such that greater cumulative marijuana use
was associated with increased thickness estimates at 3-year
follow-up. However, participants in this prior study ranged
from 16 to 19 years of age at baseline, spanning a broad neu-
rodevelopmental window. In a smaller sample of IMAGEN
participants, French et al45 reported evidence of cortical thick-
ness reductions associated with cannabis use; however,
cannabis-related cortical thickness reductions were found in
males only.
It has long been postulated that ongoing neurodevelop-
mental processes during adolescence may impart heightened
vulnerability to cannabis exposure and increase the likeli-
hood of long-term associations with cognition and behavior.
Many animal studies have reported enduring effects of ado-
lescent exposure to tetrahydrocannabinol (THC), the pri-
mary psychoactive substance in cannabis. Specifically, ado-
lescent exposure to THC has been shown to decrease social
behavior in adult rats46,47 as well as alter motivational
processes.48 Rodent and primate studies have also demon-
strated that adolescent exposure to THC results in working
memory deficits in adulthood.49-52 Several rodent studies have
also found that adolescent THC exposure results in lasting al-
terations in glutamatergic and γ-aminobutyric acid–ergic
functioning.53,54 In humans, adolescent-onset cannabis us-
ers exhibit greater use-associated problems in adulthood rela-
tive to late-onset cannabis users.55,56 Findings from the pre-
sent study may help to elucidate heightened vulnerability to
the effects of cannabis use among adolescents. We found that
the statistical map of age-related cortical change was signifi-
cantly correlated with statistical maps of the time × cannabis
interaction on cortical thickness as well as the main associa-
tion of cannabis use with cortical thickness at 5-year follow-
up. Taken together, these results suggest that, on average, can-
nabis use tended to qualify cortical thickness change within
areas already undergoing the greatest degree of age-related
change (from baseline to 5-year follow-up). This finding pro-
vides support for the association of cannabis use with ongo-
ing maturational processes in the brain and a possible expla-
nation for the heightened vulnerability to the cognitive
outcomes of cannabis use among adolescents. More impor-
tant, our imaging findings are consistent with recent animal
research on adolescent THC exposure and prefrontal cortical
maturation. Miller et al15 examined the association of adoles-
cent THC exposure with prefrontal cortical maturation using
a rat model. Researchers injected male rats with THC during
the period of their adolescence, spanning 4 to 7 weeks
of age. They found that adolescent THC exposure resulted in
distinct proximate and long-term alterations of dendritic ar-
chitecture. Specifically, THC exposure disrupted normal
neurodevelopmental processes by inducing premature prun-
ing of dendritic spines and atrophy of dendritic arbors in
early adulthood. We hypothesize that the MR imaging (MRI)–
assessed cannabis-related thinning revealed in our human
study is underpinned by the same neurobiological phenom-
enon.
Strengths and Limitations
Our study possesses several strengths that may help to ex-
plain apparent discrepancies when comparing our findings
with those of previous longitudinal imaging studies of canna-
bis use. First, all participants in the present study were report-
edly cannabis naive at baseline, and, for those who transi-
tioned to cannabis use, exposure occurred during the same
developmental window—a critical detail given that the asso-
ciations of cannabis exposure may be largely dependent on
neurodevelopmental stage. Second, the number of partici-
pants in the present study offers increased statistical power
to detect relatively subtle brain changes.
Several limitations of the present study should also be ad-
dressed. The PET data used in this study were collected on a
separate sample of young adults, not the 799 youths who un-
derwent longitudinal neuroimaging. Given the invasive na-
ture of PET imaging and its associated risks, it is not ethical to
collect PET data on minors. We cannot state definitively that,
in our sample of 799 participants, the areas exhibiting cannabis-
related thinning in longitudinal MRI analysis were, in fact, high
in CB1 receptor availability. Our present findings are also lim-
ited by the self-report nature of our cannabis use measure. As
with any self-report measure, it is possible that participants
were not honest regarding their cannabis use or that their es-
timates of past cannabis use were inaccurate. We also did not
have information pertaining to the types of cannabis prod-
ucts used (eg, cannabis oil concentrates and other formula-
tions). As in other longitudinal MRI studies, there is uncer-
tainty with regard to the exact neurobiological mechanisms
associated with MRI-assessed cortical thinning. Research sug-
gests that MRI-assessed, age-related cortical thinning may re-
flect increased myelination of lower cortical layers as op-
posed to synaptic pruning and/or neuronal cell loss.57 Natu
et al57 found good correspondence between MRI-assessed
cortical thickness and histologic measurements of cortical
thickness among young adults. This latter finding is critical
given that we detected cannabis-related differences in corti-
cal thickness at age 19 years and not at 14 years, suggesting
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that our MRI-assessed cortical thickness findings are associ-
ated with reduced cortical gray matter rather than increased
myelination. The present study focused on cortical thickness
development and did not examine potential cannabis-
related outcomes within subcortical structures. Future stud-
ies may benefit from conducting similar analyses on subcor-
tical regions, particularly those rich in CB1 receptors. Most
important, given the observational nature of the present study,
it is possible that the apparent association between cortical
thinning and cannabis use reflects preexisting trajectories of
brain maturation that were not caused by cannabis use. We can-
not rule out the possibility that preexisting cognitive and/or
behavioral differences are associated with neurodevelopmen-
tal trajectories from adolescence to early adulthood and that
cannabis use is not causally related to cerebral cortical thick-
ness development. Although such an alternative explanation
is possible, several observations from the present study are
worth reiterating. First, there was a dose-dependent associa-
tion at 5-year follow-up between lifetime cannabis use and
cortical thickness. Second, there were no significant associa-
tions between baseline cortical thickness and lifetime
cannabis use at 5-year follow-up. Given evidence of first-
order monotonic thinning for much of the cerebral cortex
during childhood and adolescence,8,33 it would seem un-
likely that differing maturational trajectories, if present,
would not have been detectable at baseline. Third, the spatial
pattern of cannabis-related thinning was significantly associ-
ated with a PET-derived map of CB1 receptor availability.
Conclusions
To our knowledge, the present investigation represents
the largest longitudinal neuroimaging study of adolescent
cannabis use to date. We report evidence of an association
between adolescent cannabis use and altered cortical thick-
ness development in a longitudinal sample of youths.
The spatial pattern of cannabis-related thinning was associ-
ated with a PET-derived map of CB1 receptor availability
as well as a map of age-related thickness change. The find-
ings underscore the importance of further longitudinal
studies of adolescent cannabis use, particularly given
increasing trends in the legalization of recreational can-
nabis use.
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